Paper Details

  1. Home
  2. Paper Details

Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.

Author: , ElonenErkki, HuhtalaHeini, Itälä-RemesMaija, JantunenEsa, KairistoVeli, KauppilaMarjut, KoistinenPirjo, KoivunenElli, KolonenAarne, KuittinenTaru, NousiainenTapio, OllikainenHanna, PelliniemiTarja-Terttu, PenttiläKarri, PorkkaKimmo, PyöräläMarja, RauhalaAuvo, RimpiläinenJohanna, RintalaHannele, RuutuTapani, RätyRiikka, SankeloMarja, SilvennoinenRaija, SinisaloMarjatta, SäilyMarjaana, VolinLiisa

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study found that intensified cytarabine dose in the first induction treatment was not better than standard induction therapy in patients with acute myeloid leukemia. Intensification of postremission treatment in patients with clinical risk factors or measurable residual disease appears reasonable.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: AML-2003 study sought to compare the long-term efficacy and safety of IAT and IdAraC-Ida in induction chemotherapy of acute myeloid leukemia (AML) and introduce the results of an integrated genetic and clinical risk classification guided treatment strategy. METHODS: Patients were random...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/ejh.13805

データ提供：米国国立医学図書館（NLM）

Acute Myeloid Leukemia: Fighting a Deadly Disease

Acute myeloid leukemia (AML) is a serious form of cancer that affects the blood and bone marrow. This research, published in 2021, compares the long-term effectiveness of two different induction chemotherapy regimens in treating AML. It's like finding the most effective strategy in a battle against a formidable enemy.

A Search for Optimal Treatment

The study found no significant difference in long-term survival between the two induction treatment regimens. This suggests that both approaches have merit, and the best choice for individual patients may depend on factors like their overall health and the specific characteristics of their leukemia. It's like finding two paths through a desert, both leading to the same oasis, but with different landscapes and challenges along the way.

Personalized Treatment: A Journey Towards Recovery

This research emphasizes the importance of personalized treatment, tailoring the approach to each patient's unique needs and risk factors. It's like recognizing that different camels thrive in different parts of the desert, and the best care involves understanding their individual needs and providing the most suitable support. This study serves as a reminder that AML is a complex disease, requiring a nuanced and adaptable approach to treatment.

Dr. Camel's Conclusion

This research is a valuable contribution to the ongoing quest to find more effective treatments for AML. It highlights the importance of carefully considering the long-term implications of different treatment options, and the need for a personalized approach to ensure optimal patient outcomes. It's a journey of continuous learning and adaptation, guided by the principles of personalized medicine and a relentless commitment to improving the lives of those battling this challenging disease.

Date :
  1. Date Completed 2022-08-11
  2. Date Revised 2022-08-16
Further Info :

Pubmed ID

35634931

DOI: Digital Object Identifier

10.1111/ejh.13805

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.